Today, seven teams started the Business Acceleration Academy program at BII. In between workshops and introductions to their workplace for the coming months, we asked Line Debois Frejlev Nielsen, CEO of MedicQuant a few questions about the first day at BII. Together with CTO Malthe Hansen-Bruhn, she has relocated from Aarhus to Copenhagen to join the intense program with their company MedicQuant that has developed a device for rapid measuring of Direct Oral Anticoagulants (DOACs) in patients in acute situations.

The BAA has officially started. How is the first day?
The first day is exciting and busy. There are a lot of new things to get familiar with, but we are already learning and have this morning been in a lecture on technology and applications so we can begin to asses our technology in respect to the market and needs.

You have had one week off since the BAA bootcamp, what have you been up to?
First and foremost, we have had to finish a lot of work at Aarhus University to be ready to commit 100 pct. to the BAA program. At the bootcamp, we laid out a plan for our months at BII and in the past week, we have also had time to reflect on and discuss how to approach it. We are ready to get started.

What was the biggest eye-opener at the bootcamp?
We come with a scientific background and we have been very focused on developing a finished product. At the bootcamp, we learned that we should focus more on the regulatory part because that is most likely more appealing to investors than a finished product. It was an eye-opener to see that there is another path than the one we were on.

Check out all the start-ups in the BII and stay tuned for more interviews.
Interesting in applying? The BAA call is open for applications.

More news from BII
“Everything we touch will be impacted by synthetic biology”
From CRISPR to AI: Seven start-ups join BII